NASDAQ:SXTC China SXT Pharmaceuticals (SXTC) Stock Price, News & Analysis $2.88 -0.11 (-3.51%) As of 12:32 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About China SXT Pharmaceuticals Stock (NASDAQ:SXTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SXTC alerts:Sign Up Key Stats Today's Range$2.80▼$2.9050-Day Range$2.73▼$301.0052-Week Range$2.71▼$8,375,880.00Volume28,257 shsAverage Volume70,338 shsMarket Capitalization$298.81 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview China SXT Pharmaceuticals, Inc. develops, manufactures and sells traditional Chinese medicine (TCM) products in China. Its offerings include regular, fine and advanced TCM pieces, which are processed medicinal materials used in preparing traditional remedies or, in some cases, consumed directly. The company serves customers such as hospitals, pharmacies, pharmaceutical manufacturers and distributors. Its business is based in China, where it operates through subsidiaries focused on processing and supplying TCM products. China SXT traces its operating history to 2005 and is headquartered in Taizhou, Jiangsu Province. The company was founded by Feng Zhou, who has been identified in company materials as its chairman and chief executive officer.AI Generated. May Contain Errors. Read More China SXT Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreSXTC MarketRank™: 1.059962854865 of 5 starsChina SXT Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingChina SXT Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageChina SXT Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about China SXT Pharmaceuticals' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted564.50% of the float of China SXT Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverChina SXT Pharmaceuticals has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in China SXT Pharmaceuticals has recently decreased by 96.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChina SXT Pharmaceuticals does not currently pay a dividend.Dividend GrowthChina SXT Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.93 News SentimentChina SXT Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for China SXT Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for SXTC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, China SXT Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders3.95% of the stock of China SXT Pharmaceuticals is held by insiders.Percentage Held by Institutions5.02% of the stock of China SXT Pharmaceuticals is held by institutions.Read more about China SXT Pharmaceuticals' insider trading history. Receive SXTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for China SXT Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SXTC Stock News HeadlinesChina SXT Pharmaceuticals (NASDAQ:SXTC) Stock Dropped to "Sell" by Wall Street ZenNovember 14 at 2:56 AM | americanbankingnews.comChina SXT Pharmaceuticals Announces 1-for-100 Share Consolidation; Stock DownOctober 22, 2026 | rttnews.comPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.November 17 at 1:00 AM | OilPrice (Ad)China SXT Pharmaceuticals, Inc. Announces Share ConsolidationOctober 22, 2026 | prnewswire.comBiotech Stocks Move Higher: IMNN Surges Over 18%, HSCS Gains Over 13%, SXTC Rises 7%October 21, 2026 | rttnews.comChina SXT Pharmaceuticals Inc Announces Termination of Additional Purchase RightOctober 21, 2026 | prnewswire.comUnivest Securities, LLC Announces Closing of $12 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)October 10, 2026 | markets.businessinsider.comChina SXT Pharmaceuticals Raises $12 Million in October Registered Direct OfferingOctober 9, 2026 | tipranks.comSee More Headlines SXTC Stock Analysis - Frequently Asked Questions How have SXTC shares performed this year? China SXT Pharmaceuticals' stock was trading at $1,920,000.00 at the beginning of 2026. Since then, SXTC shares have decreased by 100.0% and is now trading at $2.8290. When did China SXT Pharmaceuticals' stock split? China SXT Pharmaceuticals's stock reverse split on Tuesday, February 25th 2025.The 1-8 reverse split was announced on Friday, February 21st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did China SXT Pharmaceuticals IPO? China SXT Pharmaceuticals (SXTC) raised $15 million in an IPO on Friday, January 4th 2019. The company issued 3,750,000 shares at a price of $4.00 per share. How do I buy shares of China SXT Pharmaceuticals? Shares of SXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of China SXT Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that China SXT Pharmaceuticals investors own include Remark (MARK), NIO (NIO), Sintx Technologies (SINT), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Aytu BioPharma (AYTU) and Blink Charging (BLNK). Company Calendar Today11/17/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SXTC's financial health is in the Red zone, according to TradeSmith. SXTC has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SXTC CIK1723980 Webwww.sxtchina.com Phone+8652386298290FaxN/AEmployees56Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.02 Current Ratio7.94 Quick Ratio7.76 Sales & Book Value Annual Sales$1.14 million Price / Sales0.26 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares103,575Free Float5,000Market Cap$293.01 thousand OptionableNot Optionable Beta2.02 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:SXTC) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.